[Correspondence] Pembrolizumab monotherapy for advanced chordoma

We applaud Jean-Yves Blay and colleagues1 for their Article published in The Lancet Oncology, which provides further evidence that immune checkpoint inhibitors are most effective in alveolar soft part sarcoma2 and SMARCA4-deficient sarcoma,3 but with regard to the use of immune checkpoint inhibitors in advanced chordoma, we wish to express some concerns.